Specialized hematology-oncology expertise
- ~100 hematological malignancy trials
- Experience across myeloid and lymphoid malignancies
- End–to–end scientific partnership
Precision-driven Insights for Your Hematological Malignancy Research
Deliver consistent, high-sensitivity data through harmonized global labs, expert scientific support, and multimodal oncology capabilities.
Accelerating hematological malignancy programs
Hematological malignancy trials face unique pressures: small, heterogeneous patient populations, complex protocols, and the need for ultra-sensitive biomarkers.
Every phase of development, from first-in-human studies to pivotal trials, demands speed, precision, and clarity. Any missteps in data collection or analysis can slow your timelines, introduce variability, or even obscure critical biological insights.
We partner with you and your team to navigate these challenges, designing and executing studies that generate reliable, high-resolution data across modalities – from advanced flow cytometry enhanced with AI-driven analytics to genomics, cytogenetics, IHC, and routine safety testing.
By combining global consistency with advanced analytical capabilities, we ensure your data delivers the clarity and confidence needed to move crucial therapies forward.
Why choose us for your hematological malignancy trial?
Fully integrated specialty testing
- Flow cytometry, including CAR-T panels
- Next-generation sequencing (NGS) with a 176-gene extended panel (and much more)
- Cytogenetics and fluorescence in-situ hybridization (FISH)
- Integrated histopathology workflows with 250+ biomarkers and protocols
Globally harmonized delivery
- Reproducible results across our global Centers of Excellence
- Standardized instruments across US, EU, and APAC
- Unified data analysis templates and QC review
Turning complex biology into actionable insights
With our integrated laboratory capabilities, you can understand disease mechanisms, evaluate treatment response, and refine patient stratification across every phase.
Flow cytometry and immune
Flow cytometry is foundational to the diagnosis, staging, response assessment, and minimal residual disease (MRD) evaluation of liquid tumors.
Our global network offers high-parameter Cytek Aurora™ spectral flow and BD FACSLyric™ conventional flow for comprehensive immunophenotyping, receptor occupancy, cell activation/exhaustion status, CAR-T enumeration, and multi-panel immune profiling.
To help you translate high-dimensional flow cytometry data into clear, decision-ready insights, we apply Ozette’s AI-enabled analytics that standardize data processing, enhance quality control, and improve reproducibility across studies and sites.
Tissue and spatial pathology
Liquid tumors often require tissue-level investigation to characterize malignant infiltration, nodal disease, or extramedullary involvement. We offer:
- 250+ IHC assays supporting lymphoma and plasma-cell diagnostics
- Digital pathology with Halo® and Visiopharm®
- Multiplex IHC panels (immune contexture, BCMA, T-cell infiltrates)
- Spatial transcriptomics with NanoString GeoMx®
Fluorescence in-situ hybridization (FISH) and RNAScope® ISH for cytogenetic drivers and gene rearrangements
Genomics and cytogenetics
Molecular and cytogenetic analyses reveal the underlying drivers of hematological malignancies, informing diagnosis, risk stratification, and therapeutic decision-making. Our capabilities include:
- NGS broad panels across hematological malignancies, including multiple myeloma (MM), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), and lymphoids
- Whole exome and whole genome sequencing
- TCR/BCR sequencing
- Digital droplet PCR (ddPCR) for JAK2 V617F, MYD88, VCN, and others
- Quantitative PCR (qPCR) for BCR-ABL, AML1-ETO / RUNX1 – RUNX1T1, PML-RARA, CBFB – MYH11, and more
- Broad cytogenetics and FISH portfolio across all hematological cancers.
Immunogenicity, PK and safety testing
Comprehensive support for biologics, bispecifics, antibody-drug conjugates, and cell and gene therapies, including:
- ADA and NAb detection (ELISA, ELLA, MSD)
- PK assays and exposure-response evaluation
- Multiplex cytokine profiling (37-plex)
- Routine safety labs: hematology, biochemistry, coagulation, urinalysis, serology, and more.
Delivering measurable clinical impact
~100
hematological malignancy trials supported
~14,500
patients screened across global programs
~12,400
patients randomized
16
market authorizations and expansions, including multiple myeloma
3
CAR-T cell therapy approvals supported
Global labs and Centers of Excellence for hematological malignancies
With unified SOPs, validated platforms, and shared quality systems across the world, we ensure your trials stay on track, no matter where they take place.
Flow cytometry:
United States, Belgium, Taiwan, China, Australia
Genomics:
France, Netherlands, United States, Taiwan
Histopathology and IHC:
United States, France, Taiwan, China
Technologies used in hematological malignancy programs
Our liquid tumor programs leverage cutting-edge technologies across flow cytometry, genomics, and spatial pathology to deliver precise, reproducible data that drives confident clinical decisions worldwide.
Conventional flow cytometry (BD FACSLyric™)
High‑parameter flow cytometry (Cytek® Aurora)
AI-driven analytics for flow cytometry (Ozette)
Spatial biology and digital spatial profiling (NanoString GeoMx®, Akoya Phenolmager)
Next-generation sequencing (NGS) (Illumina®)
Long-read sequencing (Oxford Nanopore Technologies™)
Digital pathology and image analysis (Halo®, Visiopharm®)
Immunoassays (ELISA, MSD™, ELLA™)
Meet us at ASH 2026
Join us from December 12–15 in New Orleans for the 68th ASH Annual Meeting to discuss innovations in cell therapy biomarkers, multi‑omic strategies, and high‑parameter flow cytometry for hematological malignancies.
More hematological malignancy insights
Hematological Malignancies Trial Portfolio
Our teams bring the operational depth and scientific insight you need to drive meaningful impact in liquid tumor research. Explore this fact sheet for more insight into how we can accelerate your program, including results from a sponsor case study.
Multi-Omics Approaches in Hematological Malignancies
Due to the high level of heterogeneity in alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes. Learn more about our multi-modal approach to precision medicine.
Flow Cytometry for Autologous & Allogenic CAR-T: Global Validation
In this poster, first presented at ESCCA 2023, discover how Cerba Research has implemented both autologous and allogenic CAR‑T assays.
Flow Matters: The Power of Flow Cytometry in MRD Detection in Oncology
We explore the key role that flow cytometry plays in assessing MRD in clinical practice, as well as some of the principles to keep in mind when creating a flow cytometry (FCM) assay for MRD detection.
Analytical Validation of a 29-Color Spectral Flow Cytometry Panel for Broad Immunophenotyping and Functional Activity Assessment in Clinical Trials
As immunotherapy studies demand deeper insights into immune responses, advanced flow cytometry approaches are needed to comprehensively assess immune cell populations and functional activity. Learn more about our validated 29-color spectral flow cytometry panel.
Beyond Spectral Overlap: FRET-Driven Signal in TCR/CD3 Receptor Complex Staining Profile
Accurate immunophenotyping depends on careful panel design to distinguish true biological signals from fluorescence artifacts. Learn more about our study identifying FRET-mediated interactions within the TCR/CD3 receptor complex during high-parameter flow cytometry analysis.
Analytical Constraints of the Standard 6-Color TBNK Panel in Allogeneic CAR-T Cell Trials and Strategies for Resolution
The unique biology of allogeneic CAR T cells introduces new challenges for conventional TBNK assays used in clinical trials. Learn more about our optimized flow cytometry approach for precise identification and enumeration of T, B, and NK cell populations.
